First Midwest Bank Trust Division cut its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) by 17.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,500 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. First Midwest […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its price target dropped by investment analysts at The Goldman Sachs Group from $27.00 to $24.00 in a research note issued on Monday, Price Targets.com reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price indicates a potential downside […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Thursday. Several other brokerages also recently issued reports on ACAD. The Goldman Sachs Group upped their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $28.00 and gave the company […]